Home LanguageEnglish Tung Sin Biomedical EYESBRIGHT Obtains U.S. Food and Drug Administration (FDA) Import Approval, Set to Launch on Amazon to Seize North American Opportunities

Tung Sin Biomedical EYESBRIGHT Obtains U.S. Food and Drug Administration (FDA) Import Approval, Set to Launch on Amazon to Seize North American Opportunities

by Irma Katherine
435 views
Tung Sin Biomedical EYESBRIGHT secures U.S. FDA import approval, set to debut on Amazon e-commerce platform in the first quarter of 2024. (Photo via Corporate+)

TAIPEI, TAIWAN (Merxwire) – Tung Sin Biomedical announced the successful completion of the U.S. FDA food import regulations and Dun & Bradstreet (D&B) corporate certification in the fourth quarter of 2023, obtaining U.S. FDA import approval as part of the manufacturer identification information. The brand’s product has passed the scrutiny for listing on the world’s largest e-commerce platform, Amazon, showcasing Taiwan’s robust competitiveness in the biotech sector and highlighting the central mission of a verifiable health food research and development facility.

CEO of Tung Sin Biomedical, SUNG LIN TSAI, stated, “The U.S. Food and Drug Administration (FDA) updated its regulations in 2020, requiring food-related businesses to register with the FDA for exporting products to the United States. As part of the manufacturer identification information, exporters or manufacturers must first obtain a Dun & Bradstreet global code, a unique nine-digit identifier like a company’s unified registration number or personal identification number. Only after obtaining this code can products be exported to the United States. In addition, Amazon in the U.S. has strict review processes for health supplements, requiring FDA certification and the completion of relevant documentation submission for approval before listing. Tung Sin Biomedical completed the necessary registration and registration processes in the fourth quarter of 2023 and is now officially listed on the world’s largest e-commerce platform, Amazon.”

Market research data shows that the North American lutein market size leads globally. Tung Sin Biomedical gains international recognition, aggressively pursuing overseas opportunities. (Photo via Tung Sin Biomedical)

Tung Sin Biomedical’s exclusive product, EYESBRIGHT Lutein, was launched in 2021 and has been actively expanding into the U.S. and global markets since 2022, reaching consumers in 18 countries. With over 50,000 households as satisfied users, the company has received widespread consumer recognition and approval. COO Howard Lin stated, ” Tung Sin Biomedical’s global strategic goal is ‘Gathering Heat in Taiwan, Global Shopping, and World Franchise.’ The third phase, World Franchise, has officially commenced, and in the future, we will leverage the strengths and characteristics of franchise countries to allow people around the world to experience the fairness of vision verification.”

According to data from international research firm Statistics MRC, the global lutein market is estimated to be around $3.5 billion in 2023, expected to surpass $6.1 billion by 2030, with North America holding the largest market share. Recognizing this business opportunity, Tung Sin Biomedical is aggressively targeting the international market, showcasing Taiwan’s unparalleled global research and development competitiveness.

 

Media Contacts:
Tung Sin Biomedical
Wilson Tsai
+886-4-23598047
wilson@tung-sin.com
Facebook : https://www.facebook.com/TungSinloveEyes

 

SOURCE: Tung Sin Biomedical

You may also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

-
00:00
00:00
Update Required Flash plugin
-
00:00
00:00